TY - JOUR
T1 - Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma
T2 - Correlation with disease activity and patient outcome
AU - Novak, Anne J.
AU - Grote, Deanna M.
AU - Stenson, Mary
AU - Ziesmer, Steven C.
AU - Witzig, Thomas E.
AU - Habermann, Thomas M.
AU - Harder, Brandon
AU - Ristow, Kay M.
AU - Bram, Richard J.
AU - Jelinek, Diane F.
AU - Gross, Jane A.
AU - Ansell, Stephen M.
PY - 2004/10/15
Y1 - 2004/10/15
N2 - BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.
AB - BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.
UR - http://www.scopus.com/inward/record.url?scp=4944262288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4944262288&partnerID=8YFLogxK
U2 - 10.1182/blood-2004-02-0762
DO - 10.1182/blood-2004-02-0762
M3 - Article
C2 - 15251985
AN - SCOPUS:4944262288
SN - 0006-4971
VL - 104
SP - 2247
EP - 2253
JO - Blood
JF - Blood
IS - 8
ER -